Genus PLC (GNS) - Total Assets
Based on the latest financial reports, Genus PLC (GNS) holds total assets worth GBX899.00 Million GBX (≈ $109.38K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Genus PLC (GNS) net assets for net asset value and shareholders' equity analysis.
Genus PLC - Total Assets Trend (1996–2025)
This chart illustrates how Genus PLC's total assets have evolved over time, based on quarterly financial data.
Genus PLC - Asset Composition Analysis
Current Asset Composition (June 2025)
Genus PLC's total assets of GBX899.00 Million consist of 28.3% current assets and 71.7% non-current assets.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 5.3% |
| Accounts Receivable | GBX109.30 Million | 12.2% |
| Inventory | GBX80.90 Million | 9.0% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX55.30 Million | 6.2% |
| Goodwill | GBX102.80 Million | 11.4% |
Asset Composition Trend (1996–2025)
This chart illustrates how Genus PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Genus PLC stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genus PLC's current assets represent 28.3% of total assets in 2025, a decrease from 49.3% in 1996.
- Cash Position: Cash and equivalents constituted 5.3% of total assets in 2025, down from 13.8% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 12.2% of total assets.
Genus PLC Competitors by Total Assets
Key competitors of Genus PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Genus PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.94 | 1.80 | 1.72 |
| Quick Ratio | 1.32 | 1.21 | 1.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX123.10 Million | GBX120.50 Million | GBX93.60 Million |
Genus PLC - Advanced Valuation Insights
This section examines the relationship between Genus PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.45 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -12.6% |
| Total Assets | GBX899.00 Million |
| Market Capitalization | $19.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genus PLC's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genus PLC's assets decreased by 12.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genus PLC (1996–2025)
The table below shows the annual total assets of Genus PLC from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | GBX899.00 Million ≈ $109.38K |
-12.63% |
| 2024-06-30 | GBX1.03 Billion ≈ $125.19K |
+2.12% |
| 2023-06-30 | GBX1.01 Billion ≈ $122.58K |
-1.02% |
| 2022-06-30 | GBX1.02 Billion ≈ $123.85K |
+19.61% |
| 2021-06-30 | GBX851.00 Million ≈ $103.54K |
-0.51% |
| 2020-06-30 | GBX855.40 Million ≈ $104.08K |
+6.45% |
| 2019-06-30 | GBX803.60 Million ≈ $97.77K |
+1.82% |
| 2018-06-30 | GBX789.20 Million ≈ $96.02K |
-1.05% |
| 2017-06-30 | GBX797.60 Million ≈ $97.04K |
+7.92% |
| 2016-06-30 | GBX739.10 Million ≈ $89.93K |
+14.71% |
| 2015-06-30 | GBX644.30 Million ≈ $78.39K |
+10.29% |
| 2014-06-30 | GBX584.20 Million ≈ $71.08K |
-4.29% |
| 2013-06-30 | GBX610.40 Million ≈ $74.27K |
+3.77% |
| 2012-06-30 | GBX588.20 Million ≈ $71.57K |
+8.64% |
| 2011-06-30 | GBX541.40 Million ≈ $65.87K |
-0.18% |
| 2010-06-30 | GBX542.40 Million ≈ $65.99K |
+8.94% |
| 2009-06-30 | GBX497.90 Million ≈ $60.58K |
+14.20% |
| 2008-06-30 | GBX436.00 Million ≈ $53.05K |
+0.28% |
| 2007-06-30 | GBX434.80 Million ≈ $52.90K |
-4.71% |
| 2006-06-30 | GBX456.30 Million ≈ $55.52K |
+44.00% |
| 2006-03-31 | GBX316.88 Million ≈ $38.55K |
+202.94% |
| 2005-03-31 | GBX104.60 Million ≈ $12.73K |
+10.09% |
| 2004-03-31 | GBX95.01 Million ≈ $11.56K |
+32.39% |
| 2003-12-31 | GBX71.77 Million ≈ $8.73K |
-29.45% |
| 2003-03-31 | GBX101.73 Million ≈ $12.38K |
+145.07% |
| 2002-12-31 | GBX41.51 Million ≈ $5.05K |
-56.27% |
| 2002-03-31 | GBX94.92 Million ≈ $11.55K |
+164.38% |
| 2001-12-31 | GBX35.90 Million ≈ $4.37K |
-65.48% |
| 2001-03-31 | GBX104.00 Million ≈ $12.65K |
+0.64% |
| 2000-03-31 | GBX103.34 Million ≈ $12.57K |
+118.15% |
| 1999-03-31 | GBX47.37 Million ≈ $5.76K |
+22.64% |
| 1998-03-31 | GBX38.63 Million ≈ $4.70K |
+5.33% |
| 1997-03-31 | GBX36.67 Million ≈ $4.46K |
+13.73% |
| 1996-03-31 | GBX32.25 Million ≈ $3.92K |
-- |
About Genus PLC
Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as techni… Read more